HRGNHarvard Apparatus Regenerative Technology Inc.

About Harvard Apparatus Regenerative Technology Inc. (HRGN)

Harvard Apparatus Regenerative Technology Inc. (HRGN) is a Biotechnology company headquartered in Holliston, MA, United States whose shares trade over-the-counter on the OTCQB tier.

Harvard Apparatus Regenerative Technology, Inc., formerly Biostage, Inc., (HRGN or the Company) is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. The Company's technology is based on our proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company believes that its technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient's own organs or permanent artificial implants. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. The Company has two business segments and does not have significant costs or assets outside the United States.

Products and services

Harvard Apparatus Regenerative Technology, Inc., formerly Biostage, Inc., (HRGN or the Company) is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. The Company’s technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The Company believes that its technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. The Company has two business segments and does not have significant costs or assets outside the United States.

HRGN key facts

Ticker symbol

HRGN

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Holliston, MA, United States

Country of incorporation

US

Year of incorporation

2012

Employees

7

Estimated market cap

$29.57M (as of Apr 11, 2025)

Shares outstanding

15,918,979

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Harvard Apparatus Regenerative Technology Inc. leadership

• Junli He — CEO
• Hong Yu — President
• Joseph L Damasio Jr — CFO
• Shunfu Hu — Corporate Secretary
• William Fodor — Vice President
• Accounts Payable — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with H